As recently reviewed [87], among adjunct approaches currently in clinical use to enhance venetoclax efficacy in first-line treatment of CLL, the most effective are second-generation covalent BTK inhibitors, acalabrutinib, and zanabrutinib, which in combination with venetoclax, yield patient 4-year survival rates of 88% and 94%, respectively [87]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.